MONASH UNIVERSITY
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1958-01-01
- Employees
- 10K
- Market Cap
- -
Metformin Shows Promise in Reducing Knee Osteoarthritis Pain in Overweight Patients
• A six-month clinical trial found that metformin, a common diabetes medication, significantly reduced knee osteoarthritis pain in overweight patients by 31.3 points compared to 18.9 points in the placebo group.
• Researchers from Monash University and collaborating institutions suggest metformin could be used "off-label" as a safe, low-cost treatment option that may delay the need for knee replacement surgery.
• Beyond pain reduction, participants taking metformin also reported significantly improved joint stiffness and function, with only mild-to-moderate gastrointestinal side effects reported in 30% of treatment group patients.
Low LDL Cholesterol Levels Associated with Reduced Dementia and Alzheimer's Risk
• New research reveals individuals with LDL cholesterol below 70 mg/dl demonstrated a 26% lower risk of dementia and 28% lower risk of Alzheimer's compared to those with levels above 130 mg/dl.
• Statin use provided additional protection, with patients taking these medications showing a further 13% reduced risk of dementia and 12% reduced risk of Alzheimer's compared to non-statin users with similarly low LDL levels.
• The protective effect diminished as LDL levels dropped below 30 mg/dl, suggesting an optimal range for brain health, while a separate study found that fluctuating cholesterol levels in seniors increased dementia risk by 60%.
Engineered "Invisible" Brain Cells Reverse Parkinson's Symptoms in Preclinical Study
• Australian researchers have developed human brain cells with an "invisibility cloak" that evades immune detection, successfully restoring muscle function in rat models of Parkinson's disease without requiring immunosuppressant drugs.
• The engineered cells contain eight modified genes that mimic natural immune evasion mechanisms found in placenta and cancer cells, creating a potential "universal" cell line for transplantation across multiple neurological conditions.
• This breakthrough could eliminate the need for anti-rejection medications that increase infection risk and cause tissue damage, representing a significant advancement toward off-the-shelf cell therapies for conditions including Parkinson's, stroke, and Huntington's disease.
Decade-Long UK Registry Reveals Key Insights into Idiopathic Pulmonary Fibrosis Management and Future Directions
• The British Thoracic Society's analysis of the UK Idiopathic Pulmonary Fibrosis Registry provides the first comprehensive long-term data on over 5,000 IPF cases across 64 UK hospitals.
• Key findings include significant diagnostic delays with 60% of patients experiencing symptoms for over a year before their first clinic visit, and a shift in antifibrotic treatment preferences from pirfenidone to nintedanib after 2017.
• Experts are now advocating for a shift from consensus-based criteria toward personalized, data-driven approaches for early diagnosis and treatment, with initiatives like the global PRIME-PPF study aiming to refine risk stratification.
Early Combination of Statins and Ezetimibe Could Prevent Thousands of Heart Attacks, Study Finds
• Researchers from Imperial College London and Lund University found that early combination therapy with statins and ezetimibe significantly reduces the risk of subsequent heart attacks and death in cardiac patients.
• The study analyzed data from 36,000 heart attack patients, revealing that those receiving combination treatment within 12 weeks had better outcomes than patients receiving delayed treatment or statins alone.
• Implementation of early combination therapy could prevent an estimated 133 heart attacks per 10,000 patients over three years, potentially saving 5,000 heart attacks in the UK over a decade.
Lupus Research Alliance Awards $4.5 Million to Pioneer Next-Generation Cell Therapies for Lupus
• The Lupus Research Alliance has launched its Targeted Research Program on Engineered Cell Therapies for Lupus (TRP-ECT), awarding grants to 11 researchers developing innovative cellular treatments.
• Funded projects include faster CAR T cell production methods, selective targeting of harmful B cells while sparing protective ones, and novel approaches using regulatory T cells and natural killer cells.
• The initiative builds on promising clinical results where CD19 CAR T cell therapy induced complete remission in lupus patients who had failed previous treatments, potentially offering a path to drug-free disease management.
Australian Man Survives 100 Days with BiVACOR Artificial Titanium Heart in Groundbreaking Trial
• An Australian man in his 40s lived for 100 days with the BiVACOR Total Artificial Heart while awaiting a donor transplant, marking the longest period anyone has survived with this technology.
• The patient became the first person worldwide to be discharged from hospital with the artificial heart in February, demonstrating the device's potential as a long-term solution for severe heart failure.
• BiVACOR is currently raising $100 million to fund further clinical trials, with experts predicting artificial hearts could become a viable alternative for patients unable to wait for donor hearts within the next decade.
Partner Treatment Halves Bacterial Vaginosis Recurrence Rate in Landmark Trial
• A groundbreaking randomized controlled trial demonstrates that treating both women and their male partners for bacterial vaginosis reduces recurrence rates by nearly 50% compared to treating women alone.
• The study, conducted at Monash University, provides substantial evidence that bacterial vaginosis is sexually transmitted, challenging current treatment approaches for this condition affecting 21 million U.S. women.
• Male partners treated with oral metronidazole and topical clindamycin resulted in a significant reduction in BV recurrence rate from 4.2 to 1.6 per person-year in female partners.
First-in-Human Trial Launches for Novel Extracellular Vesicle Therapy in Crohn's Fistulas
• Hudson Institute researchers advance groundbreaking extracellular vesicle treatment derived from amniotic cells into clinical trials for complex perianal Crohn's disease, offering a potential cost-effective alternative to stem cell therapy.
• The first-in-human trial will evaluate the safety and efficacy of hAEC-EV therapy in 15 participants with refractory Crohn's perianal fistulas, marking the second human EV trial in Australia.
• With the global Crohn's disease market projected to reach $13.4 billion by 2026, this innovative approach could provide a more accessible treatment option for the one-third of patients who develop fistulas.
TGA Approves Wegovy for Cardiovascular Disease Prevention in Overweight Patients
• The Therapeutic Goods Administration has granted groundbreaking approval for semaglutide (Wegovy) to treat cardiovascular disease in overweight and obese patients, marking a first in Australia.
• The SELECT trial, spanning 41 countries with 17,000 participants, demonstrated a 20% reduction in cardiovascular events among overweight individuals with pre-existing heart disease but without diabetes.
• Professor Stephen Nicholls highlights that this approval establishes obesity as a major cardiovascular risk factor alongside traditional concerns like cholesterol, blood pressure, and smoking.
BlinkLab Initiates Major FDA Registration Study for Autism Diagnostic Platform
BlinkLab has launched a significant FDA registrational study for its Dx 1 platform, designed to aid in autism diagnosis. The study plans to recruit up to 1,100 children across multiple U.S. sites, with final results expected by the end of 2025 to support 510(k) FDA approval. The company has also partnered with Monash University for the MAGNET study to enhance its diagnostic capabilities for autism and ADHD.
Aravax Appoints Aled Williams as CBO to Spearhead International Expansion of Peanut Allergy Therapy PVX108
• Aravax appointed Aled Williams as Chief Business Officer to bolster its international presence and strategic partnerships.
• Williams will focus on expanding the Aravax portfolio and advancing the asset strategy, leveraging his 25 years of biotech and pharma experience.
• The appointment supports the Phase 2 development of PVX108, Aravax's lead immunotherapy for peanut allergy, designed for safer and more targeted treatment.
• Aravax aims to establish itself as a leader in food allergy treatments through innovative immunotherapies and strategic global outreach.
Immuron's Travelan Shows Promise in Phase 2 Trial for Traveler's Diarrhea
• Immuron has submitted the Clinical Study Report to the FDA for its Phase 2 trial of Travelan for Enterotoxigenic Escherichia Coli (ETEC).
• The study demonstrated statistically significant lower levels of IgA and IgG in subjects receiving Travelan compared to placebo, indicating reduced ETEC antigen exposure.
• Travelan recipients showed a statistically significant reduction in CFUs in stools (p=0.0121), suggesting faster clearance of the ETEC strain from the GI tract.
• Microbiome analysis revealed that Travelan promotes a more stable gut microbiota and increases beneficial bacteria linked to reduced inflammation.
Bacteriophages: A Potential Ally Against Superbugs
Researchers are exploring bacteriophages, viruses that infect and kill bacteria, as a potential solution to combat antimicrobial resistance (AMR), a growing global health threat. With the discovery of a bacteriophage in Merri Creek, Melbourne, capable of eliminating resistant Klebsiella pneumoniae, and ongoing clinical trials worldwide, phage therapy is emerging as a promising tool in the fight against superbugs.
BTK Degraders Show Promise in Pretreated B-Cell Malignancies
• Novel BTK degraders like AC676, NX-5948, and BGB-16673 are under evaluation in phase 1 trials for relapsed/refractory B-cell malignancies, addressing resistance to BTK inhibitors.
• BGB-16673 demonstrated encouraging response rates in follicular lymphoma (50%) and marginal zone lymphoma (67%), with manageable safety profiles in heavily pretreated patients.
• NX-5948 showed a 75.5% objective response rate in relapsed/refractory CLL/SLL, with a tolerable safety profile and ongoing studies planned for pivotal trials in 2025.
• AC676, a novel BTK chimeric degrader, is in phase 1 dose escalation, showing potential for treating B-cell malignancies, including those with central nervous system involvement.
Cyclarity Therapeutics Launches First-in-Human Trial of UDP-003 for Atherosclerosis
• Cyclarity Therapeutics has initiated a Phase 1 clinical trial in Australia to evaluate UDP-003, a drug targeting atherosclerosis.
• The trial will assess the safety and potential efficacy of UDP-003 in removing arterial plaques by targeting oxidized cholesterol.
• UDP-003 aims to convert foam cells back into healthy macrophages, enabling them to clear plaque buildup in arteries.
• The trial includes both healthy volunteers and patients with acute coronary syndrome to explore safety and preliminary efficacy.
Landmark Cardiology Advancements: Novel Therapies and Key Trial Results in 2024
• Tirzepatide shows promise in reducing heart failure hospitalization or cardiovascular death by 38% in obese patients with HFpEF.
• Finerenone demonstrates a 16% reduction in cardiovascular death and heart failure hospitalizations in patients with HFmrEF/HFpEF.
• Semaglutide reduces major kidney disease events by 24% and cardiovascular death by 29% in patients with type 2 diabetes and chronic kidney disease.
• FDA approves semaglutide for cardiovascular risk reduction in adults with cardiovascular disease and obesity, marking a milestone for weight loss medications.
Zanubrutinib Demonstrates Durable Efficacy and Favorable Safety in CLL/SLL Treatment
• Long-term data show zanubrutinib maintains high response rates and durable remission in CLL/SLL patients, particularly in treatment-naïve individuals, with over 75% remission at six years.
• Cardiovascular monitoring is crucial when prescribing zanubrutinib and other BTK inhibitors to mitigate risks like hypertension and atrial fibrillation.
• Ongoing studies explore zanubrutinib combinations, such as with sonrotoclax, showing promise for improved efficacy and progression-free survival in CLL/SLL.
Lilly's Muvalaplin Significantly Reduces Lipoprotein(a) Levels in Phase 2 Trial
• Muvalaplin, an oral Lp(a) inhibitor, significantly reduced lipoprotein(a) levels in adults at high risk for cardiovascular events in a Phase 2 trial.
• The study met its primary endpoint, demonstrating placebo-adjusted Lp(a) reductions of up to 85.8% at the highest dose (240 mg) after 12 weeks.
• Muvalaplin also achieved statistically significant results in secondary endpoints, including Lp(a) levels below 125 nmol/L and apoB reductions.
• The oral drug offers a potential alternative to injectable Lp(a) therapies, addressing a critical unmet need in cardiovascular disease management.
Oral Muvalaplin Shows Promise in Lowering Lipoprotein(a) Levels in Phase 2 Trial
• Muvalaplin, an oral drug by Eli Lilly, significantly reduced lipoprotein(a) (Lp(a)) levels in a Phase 2 trial, offering a potential non-injectable treatment option.
• The trial demonstrated dose-dependent Lp(a) reduction, with up to 85.7% decrease at the 240 mg dose after 12 weeks, and was generally well-tolerated by participants.
• Muvalaplin also reduced oxidized phospholipids, suggesting a mechanistic role in mitigating the relationship between Lp(a) and atherosclerotic disease.
• The study highlights the need for increased Lp(a) testing coverage to identify and treat individuals at high cardiovascular risk.
© Copyright 2025. All Rights Reserved by MedPath